Instil Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our wholly owned subsidiary, Complex Therapeutics LLC, owns a manufacturing facility in Tarzana, California and in July 2024 it leased the facility to AstraZeneca. The facility consists of 128,097 square feet of clinical and commercial manufacturing space.
Our headquarters is located in Dallas, Texas and consists of 5,055 square feet of leased office space under a lease that expires in April 2026. We also lease 7,728 square feet of leased laboratory and office space in Alderley Park, United Kingdom, under three leases that expire in November 2026.
We believe that our current facilities are adequate for our current needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.